S14 Ep2: FDA Approval Insights: Zongertinib in HER2-Mutated NSCLC: With Ticiana Leal, MD, and Misako Nagasaka, MD, PhD
OncLive® On Air - Un pódcast de OncLive® On Air
Leal and Nagasaka discussed the significance of the FDA approval of zongertinib for previously treated patients with HER2 TKD–mutant advanced NSCLC.
